TFA Therapeutics annual gross margin
2021
2022
2023
2024
2025
TFA Therapeutics's gross margin was 61.09% for fiscal 2025.
View full TFA Therapeutics company overview| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 61.09% | −11.23 pp |
| 2024 | 2024-12-31 | 72.32% | −14.52 pp |
| 2023 | 2023-12-31 | 86.84% | +12.63 pp |
| 2022 | 2022-12-31 | 74.21% | +94.25 pp |
| 2021 | 2021-12-31 | −20.04% | — |
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|
Across the available reported history, TFA Therapeutics's gross margin decreased from 72.32% to 61.09%, a change of −11.23 percentage points.
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review TFA Therapeutics filings at SEC.gov ↗